PDCD6IP

Programmed cell death 6-interacting protein · Q8WUM4 · PDCD6IP on Sugi Atlas →

0 patent compounds predicted against PDCD6IP, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDCD6IP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
co Ihibtory Receptor in Preeclampsia PHASE4UNKNOWN
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
CISH Inactivated TILs in the Treatment of NSCLC PHASE1/PHASE2WITHDRAWN
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma PHASE2UNKNOWN
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary PHASE2UNKNOWN
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype PHASE2ACTIVE_NOT_RECRUITING
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas PHASE2UNKNOWN
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease PHASE2COMPLETED
Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer PHASE1RECRUITING
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Effect of Severe Trauma on PD1 and Its Legend (PD1/L1) on T Lymphocytes and Correlation With Mortality nanUNKNOWN
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Consortium On Risk for Early-onset Parkinson's Disease (CORE PD) nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy nanCOMPLETED
Patient-Derived Organoids to Functionally Characterize Chemotherapy Resistance in Breast Cancer nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PDCD6IP binder may also engage these)

ProteinNameSimilarity
Q9WU78 1.000 Q9WU78 →
Q9W6C5 1.000 Q9W6C5 →
Q9QZA2 1.000 Q9QZA2 →
P79020 0.986 P79020 →
Q5KU05 0.986 Q5KU05 →
Q51NJ3 0.982 Q51NJ3 →
Q7SAN9 0.981 Q7SAN9 →
Q0JRZ9 0.979 Q0JRZ9 →
Q5R807 0.979 Q5R807 →
Q00004 0.979 Q00004 →
C8V212 0.978 C8V212 →
Q3UQN2 0.977 Q3UQN2 →
Q8CI04 0.977 Q8CI04 →
P34552 0.976 P34552 →
Q4IBS9 0.976 Q4IBS9 →
SRP68 Signal recognition particle subunit SRP68 0.976 landscape →
A1A4I9 0.976 A1A4I9 →
Q28Z41 0.976 Q28Z41 →
Q66HC5 0.975 Q66HC5 →
Q8I190 0.975 Q8I190 →
Q4X0Z5 0.975 Q4X0Z5 →
Q3SYW6 0.975 Q3SYW6 →
A3KQV2 0.975 A3KQV2 →
D3ZYR1 0.975 D3ZYR1 →
B3NML0 0.974 B3NML0 →
Q7S532 0.974 Q7S532 →
B4HMY3 0.974 B4HMY3 →
Q4PHA8 0.974 Q4PHA8 →
A2APV2 0.974 A2APV2 →
B4LNA1 0.974 B4LNA1 →